Latest Articles

Lp(a) as ASCVD risk factor

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

Relationship Between LDL-C LLTs and Risk of Stroke

Possible Challenges Post One Year of ESC/EAS Guidelines

Saudi initiatives on Bronchiolitis Recommendations

The first choice of RSV prevention is Nirsevimab; alternatively, palivizumab is to be considered in case of unavailability of Nirsevimab.

Implementing Beyfortus successfully (FR)

Implementing Beyfortus successfully (US)

Beyfortus in Action ECMMID

Implementing Beyfortus successfully